A 60-week, Phase IIIb, Randomized, Multi-center Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PROUD Study)
Latest Information Update: 29 Apr 2025
At a glance
- Drugs Brolucizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Registrational; Therapeutic Use
- Acronyms PROUD
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 30 Sep 2025 to 31 Oct 2025.
- 25 Apr 2025 Planned primary completion date changed from 30 Sep 2025 to 31 Oct 2025.
- 25 Apr 2025 Status changed from recruiting to active, no longer recruiting.